Search Results
Your search for ,aLl matches 18306 pages
Showing 18201 - 18250ASCO 2013: More than 20% of African American Women Carry Inherited Mutations in at Least One Breast Cancer Susceptibility Gene
A genomic profiling study of African American women with breast cancer found that about one in five carries an inherited abnormality in at least 1 of 18 genes associated with breast cancer susceptibility. Such mutations were more prevalent among women with aggressive triple-negative breast cancer,...
ASCO 2013: Less Lymphedema with Axillary Radiotherapy than Node Dissection, but Comparable Disease Control
A European phase III clinical trial found that lymphedema was twice as common among women with sentinel lymph node–positive early breast cancer who had axillary lymph node dissection compared to those who had axillary radiotherapy. Overall and disease-free survival 5 years after treatment...
ASCO 2013: Weekly Paclitaxel Is Less Toxic but as Effective for Women with Higher-risk Early-stage Breast Cancer
Low-dose weekly administration of paclitaxel resulted in equal progression-free survival but reduced overall toxicity compared to every-2-week dose-dense administration for women with higher-risk early-stage breast cancer who have undergone surgery, according to a phase III randomized trial....
ASCO 2013: Cervical Cancer Screening Using Visual Inspection with Vinegar Reduces Mortality by 31% in Large Study in India
Cervical cancer mortality was reduced by 31% over a period of 15 years among women screened with biennial visual inspection with acetic acid (VIA), or vinegar, delivered by primary health workers in a large randomized study conducted among 150,000 women in India. The researchers estimate this...
FDA Approves Lenalidomide for Patients with Relapsed or Refractory Mantle Cell Lymphoma
The U.S. Food and Drug Administration today approved lenalidomide (Revlimid) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (Velcade). Clinical Trial The approval was based on the results ...
ASCO 2013: Adding Bevacizumab to Standard First-line Chemoradiation for Glioblastoma Does Not Improve Overall Survival
A randomized phase III study found no improvement in overall survival after the addition of bevacizumab (Avastin) to standard first-line chemoradiation for glioblastoma. Patients who received bevacizumab also experienced more side effects compared to those treated with chemoradiation alone. The...
ASCO 2013: Cetuximab Offers Survival Advantage over Bevacizumab When Combined with FOLFIRI for First-line Treatment of Advanced Colorectal Cancer
First-line cetuximab (Erbitux) plus FOLFIRI chemotherapy (leucovorin, fluorouracil [5-FU], irinotecan) offered a roughly 4-month survival advantage over bevacizumab (Avastin) plus FOLFIRI for patients with KRAS wild-type metastatic colorectal cancer in the German phase III clinical trial FIRE-3. A ...
In the Clinic: Trametinib in Unresectable or Metastatic Melanoma with BRAF V600E or BRAF V600K Mutation
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 29, 2013, trametinib (Mekinist) was...
ASCO 2013: Nivolumab Produces Durable Responses in Patients with Stage IV Melanoma
Long-term follow-up results from an expanded phase I study indicate that nivolumab produced long-lasting responses in patients with stage IV melanoma. Overall, 33 out of 107 patients (31%) treated with five different doses of nivolumab experienced tumor shrinkage of at least 30% and responses were...
ASCO 2013: Most U.S. Oncologists Report High Career Satisfaction, but Many Suffer Symptoms of Burnout
Although a majority of U.S. oncologists report satisfaction with their careers, many say they have experienced at least one symptom of burnout, according to a Mayo Clinic–led study released during the ASCO 2013 Annual Meeting (Abstract 6533). “Oncology can be a tremendously rewarding...
ASCO 2013: Anti–PD-1 Antibody Produces Durable, Ongoing Response in Patients with Advanced Melanoma
Preliminary results of an ongoing trial suggest that the anti–PD-1 antibody lambrolizumab has significant antitumor activity in patients with advanced melanoma and is well tolerated. The data were presented by Antoni Ribas, MD, PhD, Professor of Hematology/Oncology and Surgery, and Director...
ASCO 2013: Everolimus Significantly Delays Tumor Growth in Women with HER2-positive Advanced Breast Cancer
The addition of everolimus (Afinitor), an mTOR inhibitor, to trastuzumab (Herceptin) and vinorelbine significantly extended progression-free survival in women with HER2-positive advanced breast cancer, compared to treatment with placebo plus trastuzumab and vinorelbine, in the phase III BOLERO-3...
Experts Call for Breast Cancer Trials Aimed at Younger Patients
A lack of clinical trials aimed specifically at younger patients with breast cancer could be partly to blame for their poor survival rates, according to a study published in the Journal of the National Cancer Institute. Study Details The study analyzed 2,956 women diagnosed with breast cancer...
New Method to Test Breast Lesions Could Better Detect Cancer and Reduce Repeat Biopsies
A newly developed, single-step Raman spectroscopy algorithm has the potential to simultaneously detect microcalcifications and enable diagnosis of the associated breast lesions with high precision, according to data published in Cancer Research, a journal of the American Association for Cancer...
Frequent Heartburn May Predict Cancers of the Throat and Vocal Cord
Frequent heartburn was positively associated with cancers of the throat and vocal cord among nonsmokers and nondrinkers, and the use of antacids, but not prescription medications, had a protective effect, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of...
New Research Shows Significant Improvement in Overall Survival Outcomes for Patients Receiving Blood Stem Cell Transplants
Survival rates have increased significantly among patients who received blood stem cell transplants from both related and unrelated donors, according to a study published in the Journal of Clinical Oncology. The study authors attribute the increase to several factors, including advances in HLA...
Mayo Clinic Genomic Analysis Lends Insight to Prostate Cancer
Mayo Clinic researchers have used next-generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings appear online today in the journal Cancer Research. Gleason Patterns...
Intensified Liposomal Daunorubicin May Offer High Survival Rates without Added Cardiotoxicity for Children with Leukemia
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at an intensified dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online in Blood, the...
Phase II Trial Targeting Genetic Anomaly in Castration-resistant Metastatic Prostate Cancer Underway
A new clinical trial is testing whether targeting treatments to a genetic anomaly can lead to better treatments for castration-resistant metastatic prostate cancer. The trial, led by investigators at the University of Michigan Comprehensive Cancer Center, is being conducted at 11 sites throughout...
Low-dose CT Detects Twice as Many Early-stage Lung Cancers as Chest X-ray, According to Additional NLST Results
Physicians have more information to share with their patients about the benefits and risks of low-dose computed tomography (CT) lung cancer screening following the publication in the New England Journal of Medicine of the results of the first (of three planned) annual screening examinations from...
Inflammatory Bowel Disease Raises Risk of Melanoma
Patients with inflammatory bowel disease are at higher risk of melanoma, reported researchers at Mayo Clinic. Researchers found that inflammatory bowel disease is associated with a 37% greater risk for the disease. The findings were presented at the Digestive Disease Week 2013 conference in...
Beta-blockers May Boost Chemotherapy Response in Neuroblastoma
Beta-blockers, normally used for high blood pressure, could enhance the effectiveness of chemotherapies in treating neuroblastoma, according to a new study published today in the British Journal of Cancer. Early Results Promising Researchers from the Children’s Cancer Institute Australia...
Genetic Diversity Predicts Outcomes in Head and Neck Cancer
A new measure of the heterogeneity of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer. In the May 20 issue of the journal Cancer, investigators at Massachusetts General Hospital (MGH) and Massachusetts Eye and Ear...
Molecular Marker from Pancreatic 'Juices' Helps Identify Pancreatic Cancer
Researchers at Mayo Clinic have developed a promising method to distinguish between pancreatic cancer and chronic pancreatitis, two disorders that are difficult to tell apart. A molecular marker obtained from pancreatic “juices” can identify almost all cases of pancreatic cancer, their...
ASCO 2013: Routine Surveillance Imaging Scans Add Little to Detection of Relapse in Patients with Diffuse Large B-cell Lymphoma
A large study reports that the vast majority of diffuse large B-cell lymphoma relapses are detected based on symptoms, abnormal blood tests or abnormal findings on physical exam, suggesting that CT scans, which are currently a routine part of follow-up, may be unnecessary. Researchers found that...
ASCO 2013: Surveillance Following Surgery Is Sufficient for Men with Stage I Seminoma
A long-term study of men with stage I seminoma, a common form of testicular cancer, suggests that surveillance for cancer recurrence, rather than additional chemotherapy or radiation therapy, is sufficient for the vast majority of men who have undergone successful surgery for their cancer....
ASCO 2013: PARP Inhibitor Shows Activity in Pancreatic, Prostate Cancers among Patients Carrying BRCA Mutations
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers ...
ASCO 2013: Anti–PD-L1 Drug Shows Promising Anticancer Effects in a Variety of Advanced Cancers
A phase I expansion study of the investigational drug MPDL3280A— an engineered PD-L1 targeted antibody—shows impressive tumor shrinkage rates in patients with several different cancers—including lung, melanoma, kidney, colorectal, and gastric cancers—that had progressed...
ASCO 2013: Men’s Fitness in Middle Age Protects against Developing and Dying from Cancer Later in Life
Findings from a large, prospective 20-year study indicate that a high level of cardiovascular fitness in middle age reduces men’s risk of developing and dying from lung and colorectal cancer, two of the most common cancers affecting men. Better fitness also reduces the risk of dying from,...
Study Identifies Possible New Treatment Target for Acute Leukemia
A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with cytogenetically normal acute myeloid leukemia (AML). The study was led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital...
FDA Approves Radium-223 Dichloride for Patients with Castration-resistent Prostate Cancer
On May 15, 2013, the U.S. Food and Drug Administration approved radium Ra 223 dichloride (Xofigo) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. Radium-223 dichloride is an...
Study: Popular Diabetes Drug Does Not Improve Survival Rates after Cancer
Despite previous scientific studies suggesting that the diabetes drug metformin has anticancer properties, a new, first-of-its-kind study from Women’s College Hospital in Toronto has found the drug may not actually improve survival rates after breast cancer in certain patients. The study,...
Blocking a Single Gene Renders Tumors Less Aggressive, Johns Hopkins Researchers Find
Researchers at Johns Hopkins have identified a gene that, when repressed in tumor cells, puts a halt to cell growth and a range of processes needed for tumors to enlarge and spread to distant sites. The researchers hope that this so-called “master regulator” gene may be the key to...
Bladder Cancer Could Recur despite Bladder Removal
Patients with advanced bladder cancers that are surgically removed might need additional therapy to prevent recurrence in certain situations, a new UT Southwestern Medical Center study suggests. The 5-year international study led by researchers at UT Southwestern validates the use of a marker...
Emil ‘Tom’ Frei III, MD, Trailblazer in the Development of Combination Chemotherapy, Dies at 89
The pages of medical history are dog-eared with breakthroughs that have transformed medicine and saved lives. One of those dog-eared pages belongs to Emil Frei III, MD, known to his colleagues and friends as Tom. In the dawn of oncology, Dr. Frei, along with his associate, Emil Freireich, MD, did...
Experimental Drug Beneficial in NIH Trial to Treat a Rare Sarcoma
Patients with advanced alveolar soft part sarcoma achieved some control of their disease using the experimental anticancer drug cediranib. The results from this largest clinical trial on alveolar soft part sarcoma to date were published online ahead of print on April 29, 2013, in the Journal of...
Selective Estrogen Receptor Modulators Reduce Breast Cancer Rates by More Than a Third in Women at High Risk
Tamoxifen and three similar drugs reduce breast cancer incidence by 38% in women at an increased risk of the disease according to a Cancer Research UK study published in The Lancet today. In the most comprehensive study to date scientists calculate that one breast cancer would be prevented for...
Delays in Diagnosis Worsen Outlook for Minority, Uninsured Pediatric Retinoblastoma Patients, Study Finds
When retinoblastoma is diagnosed in racial and ethnic minority children whose families don't have private health insurance, it often takes a more invasive, potentially life-threatening course than in other children, probably because of delays in diagnosis, researchers at Dana-Farber/Children's...
Chernobyl Follow-up Study Finds High Survival Rate among Young Thyroid Cancer Patients
More than a quarter of a century after the Chernobyl nuclear disaster, many children and teenagers who developed thyroid cancer due to radiation are in complete or near remission, according to a recent study accepted for publication in The Endocrine Society’s Journal of Clinical Endocrinology ...
Bipartisan Group of 124 Lawmakers Express Concern That Medicare Cuts to Life-sustaining Cancer Drugs Threaten Patient Care
The American Society of Clinical Oncology, Community Oncology Alliance, ION Solutions, and The US Oncology Network today commended a bipartisan group of 124 lawmakers in the U.S. House of Representatives who sent a letter to the Centers for Medicare and Medicaid Services (CMS) expressing concern...
Study to Treat Deadly Form of Thyroid Cancer Shows Promise, Mayo Clinic Says
A combination of therapies may prove to be a promising advance for the treatment of anaplastic thyroid cancer based on results of a phase I clinical trial, said researchers at Mayo Clinic in Florida. Anaplastic thyroid cancer is one of the deadliest of all cancers. Nearly all patients diagnosed...
Few Breast Cancer Survivors Maintain Adequate Physical Activity Despite Benefits
Breast cancer survivors are among the women who could most benefit from regular physical activity, yet few meet national exercise recommendations during the 10 years after being diagnosed, according to a study by researchers at Fred Hutchinson Cancer Research Center. Prior studies and available...
The U.S. Supreme Court Hears Arguments Challenging Patents on Breast and Ovarian Cancer Genes
The U.S. Supreme Court heard arguments Monday in a case seeking to invalidate patents on two genes associated with hereditary breast and ovarian cancer. The American College of Medical Genetics and Genomics (ACMG) was one of the first plaintiffs to sign onto this historic legal case. ACMG was also ...
Some Minorities Believe They Are Less Likely to Get Cancer Compared to Whites, Moffitt Cancer Center Study Shows
Researchers at Moffitt Cancer Center and colleagues analyzed national data to investigate the differences in cancer prevention beliefs by race and ethnicity. They found that minorities, including blacks, Asians, and Hispanics, have differing beliefs about cancer prevention and feel they are...
Mammogram Tool Improves Some Breast Cancer Detection but Also Increases False Alarms
A costly and widely used mammography add-on increases detection of noninvasive and early-stage invasive breast cancer but also makes more mistakes than mammography alone, researchers from UC Davis and the University of Washington have found. A new study shows that computer-assisted detection (CAD) ...
Key Bone Marrow Protein Identified as Potential New Leukemia Treatment Target
A new study on how the progression of acute lymphocytic leukemia (ALL) is influenced by the bone marrow environment has demonstrated for the first time that targeting a specialized protein known as osteopontin may be an effective strategy to increase the efficacy of chemotherapy in patients with...
Asbestos Exposure, Asbestosis, and Smoking Combined Greatly Increase Lung Cancer Risk
The chances of developing lung cancer associated with asbestos exposure, asbestosis, and smoking are dramatically increased when these three risk factors are combined, and quitting smoking significantly reduces the risk of developing lung cancer after long-term asbestos exposure, according to a new ...
NIH Trial Shows Promising Results in Treating Primary Mediastinal B-cell Lymphoma
Patients with primary mediastinal B-cell lymphoma who received infusions of chemotherapy, but who did not have radiation therapy to the mediastinum, had excellent outcomes, according to clinical trial results. Until now, most standard treatment approaches for patients with this type of...
Joint Statement on the President's Budget from ASCO, Community Oncology Alliance, ION Solutions, and the US Oncology Network
The President has released his proposed budget for fiscal year 2014, which proposes new reductions for cancer care services. Taken in combination with existing strains imposed by sequestration, this proposal threatens access to care for some of America's most vulnerable: elderly patients with ...
Adding Cetuximab to Chemotherapy Enables Select Patients with Advanced Colorectal Cancer and Liver Metastasis to Undergo Surgery
New results from a clinical trial conducted in Shanghai, China, indicate that adding cetuximab (Erbitux) to standard chemotherapy enables some patients with otherwise inoperable liver metastases due to colorectal cancer have their metastases surgically removed. Such surgery can be curative, and is...
